Suppr超能文献

闭塞性细支气管炎综合征0p期在慢性肺移植物抗宿主病中的预测价值。

Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung.

作者信息

Abedin Sameem, Yanik Gregory A, Braun Thomas, Pawarode Attaphol, Magenau John, Goldstein Steven C, Levine John E, Kitko Carrie L, Couriel Daniel R

机构信息

Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

Blood and Marrow Transplant Program, University of Michigan Health System, Ann Arbor, Michigan.

出版信息

Biol Blood Marrow Transplant. 2015 Jun;21(6):1127-31. doi: 10.1016/j.bbmt.2015.02.006. Epub 2015 Feb 14.

Abstract

Bronchiolitis obliterans syndrome (BOS) is a significant post-transplant complication with low survival. BOS stage 0p (BOS 0p) is a parameter detected on pulmonary function tests (PFTs) after lung transplantation to identify patients at risk to develop BOS. We performed a retrospective study on 442 patients who underwent allogeneic stem cell transplant from 2007 to 2011 to evaluate whether development of BOS 0p is a risk factor in this population for BOS. Patients who met criteria for BOS 0p were significantly more likely to develop BOS (hazard ratio [HR], 3.22; P < .001). BOS 0p was significantly associated with a history of lung disease pretransplant (HR, 2.48; P = .001) and chronic graft-versus-host disease (GVHD) outside the lung post-transplant (HR, 23; P < .001). Finally, BOS 0p criteria were adequately sensitive in predicting BOS (85%), with a high negative predictive value (98%). Our findings suggest a routine PFT screening strategy with the intent of detecting BOS 0p, especially among patients with prior lung disease and who developed chronic GVHD, could suitably identify an at-risk population for the development of BOS.

摘要

闭塞性细支气管炎综合征(BOS)是一种严重的移植后并发症,生存率较低。BOS 0p期是肺移植后肺功能测试(PFT)检测到的一个参数,用于识别有发生BOS风险的患者。我们对2007年至2011年接受异基因干细胞移植的442例患者进行了一项回顾性研究,以评估BOS 0p的发生是否是该人群发生BOS的危险因素。符合BOS 0p标准的患者发生BOS的可能性显著更高(风险比[HR],3.22;P <.001)。BOS 0p与移植前肺部疾病史(HR,2.48;P =.001)和移植后肺部以外的慢性移植物抗宿主病(GVHD)显著相关(HR,23;P <.001)。最后,BOS 0p标准在预测BOS方面具有足够的敏感性(85%),阴性预测值较高(98%)。我们的研究结果表明,旨在检测BOS 0p的常规PFT筛查策略,特别是在有既往肺部疾病且发生慢性GVHD的患者中,可以适当地识别出有发生BOS风险的人群。

相似文献

1
Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung.
Biol Blood Marrow Transplant. 2015 Jun;21(6):1127-31. doi: 10.1016/j.bbmt.2015.02.006. Epub 2015 Feb 14.
5
Whole-Body Lung Function Test-Derived Outcome Predictors in Allogenic Stem Cell Transplantation.
Biol Blood Marrow Transplant. 2019 Jan;25(1):129-136. doi: 10.1016/j.bbmt.2018.07.036. Epub 2018 Jul 29.
7
Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant. 2012 Oct;18(10):1479-87. doi: 10.1016/j.bbmt.2012.03.008. Epub 2012 Mar 24.
8
Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant. 2014 Aug;20(8):1169-75. doi: 10.1016/j.bbmt.2014.04.008. Epub 2014 Apr 13.

引用本文的文献

2
Pulmonary GvHD: is it time to change the NIH diagnostic criteria?
Clin Hematol Int. 2024 Oct 19;6(4):69-73. doi: 10.46989/001c.124551. eCollection 2024.
3
Clinical impact of airflow obstruction after allogeneic hematopoietic stem cell transplantation.
Int J Hematol. 2024 Oct;120(4):501-511. doi: 10.1007/s12185-024-03831-y. Epub 2024 Aug 27.
5
Diagnosis of Post-Hematopoietic Stem Cell Transplantation Bronchiolitis Obliterans Syndrome in Children: Time for a Rethink?
Transplant Cell Ther. 2024 Aug;30(8):760-769. doi: 10.1016/j.jtct.2024.05.012. Epub 2024 Jun 18.
6
Early and rapid development of bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation.
Respir Med Case Rep. 2024 Mar 11;49:102001. doi: 10.1016/j.rmcr.2024.102001. eCollection 2024.
7
Hematopoietic Stem Cells Transplant (HSCT)-Related Chronic Pulmonary Diseases: An Overview.
Children (Basel). 2023 Sep 11;10(9):1535. doi: 10.3390/children10091535.
8
Multiple breath washout and oscillometry after allogenic HSCT: a scoping review.
Eur Respir Rev. 2023 Jul 26;32(169). doi: 10.1183/16000617.0251-2022. Print 2023 Sep 30.
10
Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation.
Transplant Cell Ther. 2023 Mar;29(3):204.e1-204.e7. doi: 10.1016/j.jtct.2022.12.001. Epub 2022 Dec 9.

本文引用的文献

3
Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation.
Biol Blood Marrow Transplant. 2011 Jul;17(7):1072-8. doi: 10.1016/j.bbmt.2010.11.018. Epub 2010 Nov 30.
4
Diagnosis and staging of chronic graft-versus-host disease in the clinical practice.
Biol Blood Marrow Transplant. 2011 Feb;17(2):167-75. doi: 10.1016/j.bbmt.2010.07.017. Epub 2010 Aug 5.
6
Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.
JAMA. 2009 Jul 15;302(3):306-14. doi: 10.1001/jama.2009.1018.
9
Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients.
Am J Respir Crit Care Med. 2005 Aug 1;172(3):379-83. doi: 10.1164/rccm.200501-097OC. Epub 2005 May 13.
10
The predictive value of bronchiolitis obliterans syndrome stage 0-p.
Am J Respir Crit Care Med. 2004 Feb 15;169(4):468-72. doi: 10.1164/rccm.200307-1018OC. Epub 2003 Dec 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验